医疗器械公司 Inari Medical, Inc. (NARI) 股价在周六晚间大涨12.03%,主要受到该公司2024年第三季度财报数据超预期利好消息的推动。
财报显示,Inari Medical第三季度调整后每股亏损9美分,优于分析师预期的11美分亏损。同时,公司营收同比增长21.4%至1.5339亿美元,也超出了市场预期。
虽然Inari Medical仍处于亏损状态,但本季度业绩好于预期。公司在医疗器械领域的营收增长迅速,未来发展前景获得市场认可。目前分析师一致给予该公司"买入"评级,看好其长期成长空间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.